来凯医药-B大涨11%

Group 1 - The core viewpoint of the article highlights the significant increase in the stock price of Lakai Pharmaceutical-B, which surged by 11% following the initiation of Phase I clinical trials for its LAE102 injection in mid-October [1] - The LAE102 is a monoclonal antibody targeting ActRIIA, aimed at providing new treatment options for overweight and obese patients [1]